[Galectin-3 expression in peripheral blood mononuclear cells of chronic hepatitis B patients treated with pegylated interferon alpha-2a].
To study the relationship between therapeutic efficacy of pegylated interferon alpha-2a (Peg-IFNa-2a) in patients with chronic hepatitis B (CHB) and expression of Galectin-3 in peripheral blood mononuclear cells (PBMCs). Fifty CHB patients treated with a 48-week course of Peg-IFNa-2a (180 mug/week, subcutaneous) were divided into groups according to treatment response, with 14 patients in the 24-week responder group, 21 patients in the 48-week responder group and 15 patients in the non-responder groups. Twenty healthy volunteers served as the normal control group. Gene and protein expression of Galectin-3 in PBMCs was detected by PCR and westen blotting. PBMC expression of Galectin-3 was significantly higher in the effective treatment (responders) group compared to the control group and the non-responder group. In addition, the 24-week responders had significantly higher than the 48-week responders, and the 48-week responders had significantly higher Galectin-3 expression than the non-responders at 24 weeks. Peg-IFNa-2a may inhibit HBV DNA replication by up-regulating the expression of Galectin-3 in PBMCs.